CRISPR Therapeutics grants 17,000 RSUs to counsel

KASINGER JAMES R. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

KASINGER JAMES R. reported acquisition or exercise transactions in this Form 4 filing.

CRISPR Therapeutics AG reported that its General Counsel and Secretary, James R. Kasinger, received a grant of 17,000 restricted stock units. Each unit represents a right to receive one common share. All 17,000 units are scheduled to vest on November 29, 2028, if the vesting conditions are met.

Insider Trade Summary

Grant/Award: 17,000 shares

Grant/Award 1 txn

Insider KASINGER JAMES R.

Role General Counsel and Secretary

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	17,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 17,000 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
2. F2. This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028.

Key Figures

RSUs granted: 17,000 units Underlying common shares: 17,000 shares Vesting date: November 29, 2028 +2 more

5 metrics

RSUs granted 17,000 units Restricted stock units granted on May 29, 2026

Underlying common shares 17,000 shares Each RSU represents one common share

Vesting date November 29, 2028 100% of RSUs vest on this date

Shares after transaction 17,000 units Total restricted stock units following this grant

Grant price per share $0.00 RSUs granted as compensation, no cash exercise price

Key Terms

Restricted Stock Units, contingent right, vesting, grant, award, or other acquisition

4 terms

Restricted Stock Units financial

"The filing reports a grant of 17,000 Restricted Stock Units to the insider."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."

vesting financial

"100% of the shares vesting on November 29, 2028."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"The transaction code description states it is a Grant, award, or other acquisition."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRISPR Therapeutics (CRSP) report for James R. Kasinger?

CRISPR Therapeutics reported that General Counsel James R. Kasinger received 17,000 restricted stock units as a grant. These RSUs are a form of equity compensation tied to the company’s common shares, rather than an open-market purchase or sale of stock.

How many CRISPR Therapeutics RSUs were granted in this Form 4 filing?

The filing shows a grant of 17,000 restricted stock units to the insider. Each restricted stock unit represents a contingent right to receive one CRISPR Therapeutics common share, providing potential future ownership if the vesting requirements are satisfied.

When do the granted CRISPR Therapeutics RSUs vest for James R. Kasinger?

All 17,000 restricted stock units are scheduled to vest on November 29, 2028. Vesting means the units convert into common shares at that time, assuming the specified service or other vesting conditions continue to be met through that date.

Is this CRISPR Therapeutics Form 4 transaction an open-market stock purchase or sale?

No, the transaction reflects a grant of restricted stock units, not an open-market trade. The Form 4 categorizes it as a grant or award acquisition, representing compensation rather than a discretionary buy or sell of existing CRISPR Therapeutics shares.

What is James R. Kasinger’s reported CRISPR Therapeutics holding after this RSU grant?

After the reported grant, the Form 4 shows 17,000 derivative securities related to common shares. These represent the newly awarded restricted stock units, which may convert into the same number of common shares once the vesting date and conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 05:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KASINGER JAMES R.

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		A		17,000		(2)	(2)	Common Shares	17,000	$0	17,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028.

	Elizabeth Ryland Waldinger, attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)